Objective To investigate the clinical effect of Sulfasalazine combined with Fengliao Changweikang Capsules in the treatment of ulcerative colitis (UC).Methods A total of 76 patients with ulcerative colitis admitted to Tianyou Hospital affiliated to Wuhan University of Science and Technology from January to October 2022 were selected as the study objects.They were divided into treatment group（38 cases）and control group（38 cases）according to random number table method.The treatment group was treated with Sulfasalazine combined with Fengliao Changweikang Capsules,and the control group was treated with Sulfasalazine.The clinical efficacy,serum inflammatory factor levels and disease activity index (DAI)score of the two groups were compared.Results The total effective rate of the treatment group was higher than that of the control group,and the difference was statistically significant (P＜0.05).After 8 weeks of treatment,hypersensitive C-reactive protein(hs-CRP),tumor necrosis factor-α (TNF-α) and interleukin (IL)-10 in the treatment group were lower than those in the control group,the differences were statistically significant (P＜0.05).After 4 weeks of follow-up,hs-CRP,TNF-α and IL-10 in the treatment group were lower than those in the control group,the differences were statistically significant (P＜0.05).After 8 weeks of treatment,DAI score in the treatment group was lower than that in the control group,and the difference was statistically significant(P＜0.05).After 4 weeks of follow-up,DAI score in the treatment group was lower than that in the control group,the difference was statistically significant (P ＜0.05).Conclusion Sulfasalazine combined with Fengliang Changweikang Capsules in the treatment of UC can improve the effective rate,reduce the serum inflammatory factor level and DAI score of patients,which is worthy of clinical application.